WeVote
Log In

Bill

RB

Bill

A 3974

Prohibits use of deceptive marketing practices by substance use disorder treatment providers.

2024-2025 Regular Session Introduced by Rosy Bagolie and 21 co-sponsors

New Jersey law prohibits substance abuse treatment providers from using deceptive marketing practices to protect vulnerable patients seeking recovery services.

Approved P.L.2025, c.122.
#drugabuse #healthfac
0
WeVote Research Nonpartisan
Bill Summary · A 3974

Legislative bill overview

Bill A 3974 prohibits substance use disorder (SUD) treatment providers in New Jersey from engaging in deceptive marketing practices. The bill was unanimously passed by both the Senate and Assembly and signed into law in August 2025. It establishes standards for truthful advertising and marketing by treatment facilities and providers.

Why is this important

The SUD treatment industry has faced criticism for predatory marketing tactics that target vulnerable individuals and families seeking help. Deceptive practices—such as false claims about treatment success rates, unlicensed providers, or misleading insurance coverage information—can lead patients to seek ineffective care and delay genuine treatment. This law aims to protect consumers and ensure marketing claims are substantiated and transparent.

Potential points of contention

  • Vague enforcement mechanisms: The bill's effectiveness depends on how "deceptive" is defined and which agency enforces violations; unclear enforcement could limit real-world impact
  • Definition scope: Treatment providers may dispute what constitutes deceptive marketing (e.g., distinguishing between puffery and false claims, or subjective outcome claims)
  • Compliance costs: Smaller treatment facilities may face increased administrative burdens and legal expenses to ensure marketing compliance, potentially reducing service accessibility in underserved areas

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.